On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation

Anja U. Engela1, Carla C. Baan1, Frank J. M. E. Dor2, Willem Weimar1 and Martin J. Hoogduijn1*

1 Transplantation Laboratory, Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands
2 Department of Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands

*Correspondence: m.hoogduijn@erasmusmc.nl

INTRODUCTION TO MSC AND TREG

Since the discovery of mesenchymal stem cells (MSC) in bone marrow by Friedenstein et al. (1976), researchers were able to isolate these adherent cells from various postnatal and adult tissue sources (Pittenger et al., 1999; Zuk et al., 2002; Hoogduijn et al., 2007; Antonacci et al., 2011). MSC are self-renewing and capable of forming colonies while retaining their multilineage differentiation potential. They are able to differentiate into adipocytes, chondrocytes, osteoblasts, and myocytes (Pittenger et al., 1999; de la Garza-Rodríguez et al., 2012). These features represent part of the criteria that define MSC (Dominici et al., 2006). MSC are immunophenotypically characterized by the expression of the cell surface markers CD73, CD90, CD105, and CD146, and the absence of CD11b, CD14, CD19, CD34, CD45, and CD79α. Interest in MSC for their use in transplantation was fostered when it was first discovered that MSC possess immunosuppressive properties (Bartholomew et al., 2002). Intensive research was undertaken to unravel the mechanisms by which MSC exert their immunomodulatory functions. Besides CD4+ helper T cells and CD8+ cytotoxic T cells, activated B cells and natural killer (NK) cells are also susceptible to the suppressive activity of MSC (Corcione et al., 2006; Sotinopoulou et al., 2006). Further, MSC hamper the maturation of dendritic cells (DC) through the downregulation of MHC class II molecules and co-stimulatory molecules (Aggarwal and Pittenger, 2005; Jiang et al., 2005; Nauta et al., 2006). In addition to these immunosuppressive effects, MSC also have immunosupportive properties; they delay the apoptosis of neutrophils, preserving them to be readily available to counter infections (Raffaghello et al., 2008). Immunomodulation by MSC is mediated by cell-cell contact and the release of soluble factors. Important mediators are indoleamine 2,3-dioxxygenase (IDO), transforming growth factor-beta (TGF-β), interleukin-10 (IL-10), prostaglandin E2 (PGE2), hepatocyte growth factor (HGF), human leukocyte antigen-G5 (HLA-G5), and nitric oxide (NO; Di Nicola et al., 2002; Meisel et al., 2004; Groh et al., 2005; Batten et al., 2006; Nasef et al., 2007; Sato et al., 2007; Hoogduijn et al., 2007a; Deuse et al., 2011). The ability of MSC to exert their immunosuppressive function requires MSC activation in a pro-inflammatory microenvironment through the presence of cytokines like interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), IL-1α, and IL-1β (Crop et al., 2010). Collecting in vivo data suggest that MSC could be used as immunotherapy (Bartholomew et al., 2002; Popp et al., 2008). In clinical studies MSC have successfully attenuated graft-versus-host-disease (GvHD) after hematopoietic stem cell transplantation (Le Blanc et al., 2004, 2008). Currently, research groups strive to confirm the safety and feasibility of MSC therapy in solid organ transplantation (Hoogduijn et al., 2007b; Perico et al., 2011).

Primarily T cells are targeted by the immunosuppressive effect of MSC which raises the question, to what extent MSC affect T cells with immunomodulatory properties. Regulatory T cells (Treg) were first characterized by Sakaguchi et al. (1995) as activated CD4+ T cells expressing CD25, the IL-2 receptor alpha-chain, which are involved in the maintenance of tolerance to self-antigens. Human Treg are commonly characterized by their expression of the transcription factor forkhead box P3 (FOXP3) and the FOXP3 reciprocal expression of CD127, the IL-7 receptor alpha-chain (Fontenot et al., 2003; Liu et al., 2006; Seddiki et al., 2006); additional markers are the co-stimulatory...
molecules cytotoxic T lymphocyte antigen-4 (CTLA-4) and the glucocorticoid-induced TNF receptor-related protein (GITR; Read et al., 2000; Solomon et al., 2000; Takahashi et al., 2000; McHugh et al., 2002; Shimizu et al., 2002). While a unique marker for human Treg is yet to be identified, FOXP3 presents a reliable marker for Treg in mice (Ziegler, 2006).

The importance of Treg in the maintenance of tolerance is highlighted in humans suffering from immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX; Bennett et al., 2001; Kobayashi et al., 2001). IPEX patients lack functional Treg as a result of a point mutation in the Foxp3 gene (Bacchetta et al., 2006). In other autoimmune diseases, the role of Treg remains controversial (Buckner, 2010). The immunomodulating nature of Treg made them interesting candidates for the induction of transplantation tolerance. Indeed, Treg have been reported to control alloreactivity by inhibiting the functionality of cell types similar to those suppressed by MSC; Treg hamper the proliferation of CD4+ T cells, CD8+ T cells, and DC (Vehbius et al., 2006; Bestard et al., 2007; Tang and Bluestone, 2008; Hendriks et al., 2009a). Further, molecules associated with the tolerogenic and suppressive function of Treg partially overlap with those involved in MSC-mediated immunomodulation and include IL-10, TGF-β, and heme oxygenase-1 (HO-1; Tang and Bluestone, 2008). In addition, it has been hypothesized that Treg are able to influence their target cells in a granzyme B-dependent and perforin-dependent manner (Grossman et al., 2004; Gongde et al., 2005). Results from different humanized mouse models and clinical studies in patients with GvHD encourage the use of freshly isolated or ex vivo expanded Treg (Tzironkowska et al., 2009; Isa et al., 2010; Naidi et al., 2010; Brunstein et al., 2011; Di Ianni et al., 2011). Despite the indication that Treg therapy is promising and well tolerated in patients receiving stem cell treatment, clinical information about the application of Treg in solid organ transplantation is still lacking. However, Treg represent one of the immunomodulatory cell types whose clinical safety is currently under investigation (McMurchy et al., 2011; Schlesser et al., 2012).

Both MSC and Treg are able to influence the adaptive immune system by utilizing similar and distinct mechanisms. Therefore, it is of interest whether the overlapping mechanisms cause interference of the immunomodulatory properties of both cell types.

**IN VITRO INTERACTION BETWEEN MSC AND TREG**

Recently we investigated the interaction between MSC and Treg in a transplantation setting (Engela et al., 2012). We found that MSC derived from healthy kidney donors permitted the function of Treg from healthy donors as well as Treg from renal transplant patients. Vice versa, Treg did not hamper MSC function.

One of the first indications that T cells with a regulatory phenotype are unaffected by the suppressive capacities of MSC was provided by Maccario et al. (2005). This group reported that although autologous MSC and third-party MSC were able to suppress the proliferation of CD4+ T cells and CD8+ T cells in primary mixed lymphocyte cultures (MLC), after re-stimulation in secondary MLC the numbers of CD4+ T cells co-expressing CD25 and/or CTLA-4 increased. This indicates an MSC-dependent preferential differentiation into T cells with a regulatory phenotype. Similar observations were made by Prevosto et al. (2007) after PBMC-MSC co-culture. In addition, IL-2 stimulation of PBMC in the presence of MSC also led to elevated proportions of CD4+CD25+ T cells (Aggarwal and Pittenger, 2005). It has to be considered that due to lack of appropriate markers no distinction could be made between activated effector cells and Treg in these early research studies. Employing newly discovered markers, Di Ianni et al. (2008) performed an extensive study to shed light on the T cell population that is most responsive to the MSC-stimulus for Treg generation. The largest numbers of CD4+CD25+FOXP3+CD127− Treg were found when MSC were cultured with immunoselected CD3+CD43RA+ or CD3+CD45RO+ fractions. Co-culture of MSC with different Treg populations such as CD4+CD25+ cells, CD4+CD25+CD45RA+ cells, and CD4+CD25+CD45RO+ cells maintained FOXP3 expression, CD127 downregulation, and the immunosuppressive activities of Treg for about 2 weeks. In the absence of MSC the Treg populations lost their suppressive capacities during this period.

The apparent interplay between MSC and Treg in the allo-suppression of T cell proliferation triggered researchers’ interest in the factors and mediators involved. Although conflicting data exist, it is the current opinion that key factors involved in Treg induction by MSC are MSC-derived TGF-β and PGE2 (Prevosto et al., 2007; English et al., 2009). TGF-β is a key regulator of the initiation and maintenance of FOXP3 expression and the suppressive function of Treg (Chen et al., 2000; Fa et al., 2004). PGE2 is an immunosuppressant that inhibits T cell mitogenesis and the production of IL-2. TGF-β and PGE2 are constitutively produced by MSC. Secretion of these two immunomodulatory molecules can be increased through “MSC licensing,” the activation of MSC with TNF-α and IFN-γ which improves their immunosuppressive capacity (English et al., 2007; Ryan et al., 2007). MSC-derived PGE2 also exerts suppressive functions by increasing the IL-10 production of macrophages and by limiting monocyte differentiation into DC (Nemeth et al., 2009; Spaggiari et al., 2009). It has also been reported that PGE2 induces a regulatory phenotype in CD4+CD25+ T cells by modulating the expression of FOXP3 and therefore contributes to Treg function (Baratelli et al., 2005). In addition, cell-cell contact seems to play a non-redundant role in the induction of Treg (English et al., 2009). After culture of CD4+ cells with MSC, increases in mRNA levels of CD25 and FOXP3 mRNA were only detected when cells were in close proximity, when cells were separated by a tissue culture insert, this effect was not observed. For enhancement of FOXP3 expression in PBMC, however, direct MSC-PBMC contact was not required. This suggests that cell-cell contact between certain PBMC subpopulations contributes to the FOXP3 expression and substitutes for MSC-CD4+ cell contact interactions. Another factor influencing the immunomodulatory effect of MSC on alloactivated T cells as well as the expansion of CD4+CD25+FOXP3+ Treg is the soluble protein HLA-G5 (Selmani et al., 2008). In the presence of anti-HLA-G5 antibody, MSC-mediated immunosuppression was hampered. Neutralization of the HLA-G5 protein led to a decrease in the generation of CD4+CD25+FOXP3+ T cells. In addition, the
tryptophan-catabolizing enzyme IDO was identified as a crucial modulator of the immunosuppressive effect of MSC (Mesiel et al., 2004; Jurgens et al., 2009). Using a renal allograft model, Ge et al. (2010) investigated whether MSC-driven T cell suppression is also a consequence of the induction of Treg. Graft survival in untreated kidney recipients was significantly lower than graft survival in mice after MSC treatment. Increased serum levels of kynurenine in MSC-treated allograft recipients indicated increased IDO enzymatic activity and correlated with higher frequencies of CD4+CD25+FOXP3+ Treg in recipient spleen and in the allograft. In this model recipient treatment with IDO-knockout MSC or the IDO inhibitor 1-methyl-tryptophan did not achieve graft tolerance. Therefore, the expression of functional IDO seems to be a prerequisite for MSC-mediated graft acceptance via direct T cell suppression as well as indirect modulation of the graft recipient’s immune system through Treg induction. Skewing of CD4+ T cell differentiation toward a more regulatory phenotype leads to the inhibition of T helper 17 (Th17) cell differentiation, an effect which is partly caused by MSC-derived IDO and PGE2 (Ghannam et al., 2010; Tataru et al., 2011). The role of IL-17, produced by Th17 cells, in the onset of GVHD is still controversial. Disease-ameliorating effects and an inductive role of ex vivo differentiated Th17 cells have been reported (Carlsson et al., 2009; Kappel et al., 2009).

In summary, the mechanisms employed by MSC to inhibit effector T cell proliferation overlap with the mechanisms involved in Treg induction, yet, they do not interfere with Treg function.

**In vivo interaction between MSC and Treg**

Whether MSC-mediated in vitro induction of Treg can be translated into the in vivo setting or even into the clinical setting remains to be thoroughly investigated. To date little evidence from animal models exists. One of the first in vivo studies, reporting the induction of Treg after MSC administration, was conducted by Gonzalez et al. (2009). Mice suffering from induced colitis were treated with a systemic infusion of human MSC. Increased serum levels of kynurenine and kynurenic acid were detected while IL-4 levels were significantly increased. Further, in recipient spleens, frequencies of CD4+CD25+FOXP3+ T cells were higher in MSC-treated mice. Ge et al. (2010) also found a significant increase of intragraft FOXP3+ T cells after MSC treatment suggesting Treg recruitment to the renal allograft. In this model, depletion of Treg using an anti-CD25 monoclonal antibody also reversed the beneficial effect of MSC therapy. CD25+ T cell depletion caused graft rejection despite MSC treatment. This study again emphasized the importance of IDO as a mediator of MSC function. MSC derived from IDO-knockout mice were not able to induce graft tolerance. In a similar fashion, in vivo inhibition of IDO also abrogated the tolerogenic effect of MSC revealing a significant role of IDO in MSC immunosuppressivity.

**Interaction between MSC and Treg in the clinical setting**

Results from preclinical studies support the plethora of in vitro data and confirm that MSC-mediated induction of Treg has functional relevance in vivo. Nevertheless, to date only one clinical study looked into this aspect of MSC therapy in a transplantation setting (Peroz et al., 2011). In this safety and clinical feasibility study, autologous MSC were administered intravenously to two patients 7 days after they received living-related kidney grafts. Despite a concerning increase in serum-creatinine levels after MSC infusion, stable graft function was reported for both patients coincided with a 1-year follow-up period. Both patients received induction therapy in combination with standard maintenance immunosuppression. The induction regimen consisting of basiliximab and low-dose rabbit anti-thymocyte globulin (ATG) caused a profound depletion of CD4+ and CD8+ T cells in the peripheral blood in MSC-treated and non-MSC-treated patients during the first 30 days. In patients with MSC therapy the number of CD4+ T cells remained lower during the entire follow-up time when compared to the number of CD4+ T cells in non-MSC patients.
In contrast, CD8+ T cell repopulation to pre-transplant levels was achieved in both patient groups. During T cell depletion, the percentage of CD4+CD25+FOXP3+CD127− Treg within the total CD4+ T cell population was reduced. However, after 30 days the percentage of Treg increased in both MSC-treated patients. The memory CD8+CD45RO+RA− T cells in both MSC-treated patients remained lower than pre-transplant levels after 30 days post-transplant despite the full recovery of total CD8+ T cell counts around this time-point. This effect was less prominent in patients who did not receive MSC. These findings indicate that in comparison to the immunosuppressive medication MSC might have an additional inhibitory effect on memory CD8+ T cell proliferation. The combination of reduced memory CD8+ T cells and increased percentages of Treg suggests that MSC treatment leads to a more pro-tolerogenic environment. Yet, it cannot entirely be ruled out that the observed effects are due to the MSC treatment and not evoked by the rATG induction therapy. More clinical experience with MSC therapy is required to obtain confident data.

**INTERACTION OF MSC AND TREG WITH IMMUNOSUPPRESSIVE MEDICATION**

Achieving graft tolerance, the long-term goal in transplantation immunology, is a major challenge. Controlling the immune response to donor-antigens in the graft recipient is currently accomplished by the administration of immunosuppressive drugs. Upon the introduction of novel cellular immunotherapies they will be applied in combination with standard immunosuppressive regimens. It therefore has to be considered that these drugs may not be permissive for MSC and/or Treg function. Conversely, MSC and Treg may interfere with the efficacy of the agents.

*In vitro* studies show that MSC reduce the efficacy of rapamycin and tacrolimus and, conversely, that these immunomodulatory agents negatively affect MSC function (Hoogduijn et al., 2008; and tacrolimus and, conversely, that these immunomodulatory agents negatively affect MSC function (Hoogduijn et al., 2008; Eggenhofer et al., 2011); treatment with mycophenolate mofetil (MMF), the prodrug of mycophenolic acid (MPA) while dexamethasone did not influence MSC functionality. A synergistic effect of MSC and MPA on pro-cell proliferation has been reported for combination therapy of cyclosporine A and tacrolimus. Subsequent adoptive infusion of rapamycin had better synergistic effects on Treg function than (Thornton et al., 2010). Opinion on this topic is divided, some groups claim that Helios only presents an additional activation marker and is mutually exclusive with other Treg markers, while the TSDR in iTreg is methylated. Further discrimination between nTreg and iTreg may be provided by Helios, an Icasso family transcription factor. It has been reported that iTreg express Helios while Treg do not (Thornton et al., 2010). Heterogeneity of the Treg population is divided, some groups claim that Helios only presents an additional activation marker and is mutually expressed by natural Treg and induced Treg (Akkimov et al., 2011; Gottschalk et al., 2012).

Apart from these two Treg subsets, non-FOXp3 expressing CD4+Treg have been described such as the IL-10 expressing Treg regulatory (Tr)1 cells and TGF-β expressing Th3 cells (Weiner, 2001; Roncarolo et al., 2006). Other T cells with regulatory functions have been studied, but less extensively (Hayday and Tigelir, 2013; Ribbe et al., 2006; Ford McIntyre et al., 2008; Monteiro et al., 2010).

These new findings have to be considered when previous Treg work is evaluated. Further research will be required to investigate and to distinguish the influence of MSC on Treg expansion and Treg induction.

**THE IMPORTANCE OF TREG INDUCTION BY MSC**

The fate of MSC in the body after administration has been revealed by multiple distribution studies (Barbash et al., 2003; Kraitichman et al., 2005; Fischer et al., 2009; Assis et al., 2010; Zonta et al., 2010). Using various types of tracking techniques it was determined that MSC accumulate in the lung after intravenous infusion. The size of cultured MSC is significantly larger than the size of other immune cells in the circulation. This might cause MSC to be trapped in the capillaries of the lung. When MSC were administered via alternate routes, they were also found in other organs such as liver and spleen (Shi et al., 2010). Despite the consistency of the data, the drawback of these studies is that researchers cannot be certain that label detection confirms the presence of living MSC. Retrieved label can originate from viable MSC, deceased MSC or possibly phagocytosed debris of MSC.

To gain more clarity on this issue, different approaches have been examined (Hoogduijn et al., 2011). After intravenous
administration of labeled MSC to mice, organs were harvested, and MSC were isolated and re-cultured. Interestingly, labeled MSC were found in the lung up to 24 h after infusion, but in none of the other observed organs at any time after administration.

The apparent shortevty of MSC after infusion fortifies the importance of rapid Treg induction by MSC. While MSC are retained in different tissues briefly and subsequently cleared, they “transfer” their immunomodulatory effect to other immunosuppressive mediators. Hence, when infused MSC are not present any longer to execute their suppressive functions, increased numbers of Treg are available to enforce graft acceptance.

CONCLUSION

Although currently prescribed drug-based immunosuppressive regimen are effective in preventing graft rejection in transplant patients, their main shortcoming is that their long-term application causes malignancies, infections, and nephrotoxicity. Due to their immunomodulatory capabilities, MSC have a high potential to function as alternative immunosuppressive therapy possibly with less side effects. While drugs mainly target a specific molecular pathway to achieve immunomodulation, MSC may have a broader effect on the patient’s immune system. Yet, further characterization of this more global intervention by MSC is required. Despite inflicting their immunosuppressive effect on most lymphocyte subsets including T cells, MSC spare Treg. In fact, preclinical and clinical studies indicate that MSC mediate the expansion of natural Treg and/or the induction of novel Treg. This becomes an important feature of MSC immunomodulation as MSC appear to be cleared by the recipient’s immune system shortly after infusion and hence will not be able to perform their suppressive capacities via direct cell-cell contact or soluble factors. Because of the multifaceted mechanism by which MSC apply their immunosuppressivity combined with the fact that they do not impair the functionality of host Treg, MSC are very interesting candidates for cellular therapy in transplantation. First clinical results in the field of transplantation should encourage investigators to continue their research to bring MSC therapy to the patient.

REFERENCES

Barakhi, I. M., Chopraei, P., Baron, J., Potter, M. B., Sturzen, S., Toomey, A., Miller, L., Guitta, E., Zipori, D., Keles, I. H., Klarza, R. A., and Levine, J. D. (2007). Systemic delivery of bone marrow-derived mesenchymal stem cells to the infected myocardium feasibly: cell migration, and body distribution. Circulation 116, 856–868.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.

Battaglia, M., Stabilini, A., and Tresoldi, P. (2010). Mesenchymal stem cells suppress lymphoproliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 38, 45–56.
Deuse, T., Stubbendorff, M., Tang-Engela et al. Interactions between MSC and Treg

Dominici, M., Le Blanc, K., Mueller, A., Nicola, M., Carlo-Stella, C., Magni, Di Ianni, M., Del Papa, B., De Ioanni, A., Prockop, D., and Horwitz, E. A. M. (2002). Human bone marrow

Matsui, W. (2009). Cell contact, prostaglandin E2, and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25+Foxp3-high forkhead box P3 regulatory T cells.

Fujita, T., Demonet, P., Uchida, N., and Staudt, L. M. (2003). Foxp3 expression by CD4+CD25+ regulatory T cells in murine transplantation model.

J Invest Dermatol 121, 353–362.

To mediate T cell suppression, regulatory T cells display the surface antigen Foxp3.

Foxp3 is a master transcription factor that controls the development, maintenance and function of regulatory T cells (Tregs).

Nonspecific mitogenic stimuli.

Blood 109, 2535–2542.

Expression of Helios among human mesenchymal stem cells (MSCs) impacts their immunomodulatory function.

M-shares, A., Gordon, C., and Heeg, R. (2012). Innate immune response assessment in vitro: Which TLRs are relevant for human MSCs.

Koc, O. N. (2005). Human mesenchymal stem cell transplantation (MISOT).

Blood 109, 2385–2393.

Wu, Y., Yu, X. D., and Mao, N. (2006). Human mesenchymal stem cells have immunomodulatory activity in allogeneic T cells.

Blood 114, 3225–3235.

Kapel, I. W., Goldberg, G. L., King, C. K., Sab, D. Y., Smith, O. M., Lough, C., Helland, A. M., Grogan, I., Maak, M. N., Liu, C., Joaquin, Y., Heller, G., and van den Brink, M. B. (2009). IL-17 contributes to CD4-mediated graft-versus-host disease.

Blood 113, 945–952.

Kurashahi, H., and Mahoney, P. B. (2011). Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing immune regulatory T cells.

Cell Death DISC 2009; 9(2): 153–157.

Ohta, K., Yagi, Y., and Ikeda, T. (2009). Interleukin-17 contributes to CD4-mediated graft-versus-host disease.

Blood 113, 945–952.

Kurashahi, H., and Mahoney, P. B. (2011). Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing immune regulatory T cells.

Cell Death DISC 2009; 9(2): 153–157.
Kohanchuk, E. (2001). Novel mutations of FOXP3 in two Japanese patients with autoimmune polyendocrinopathy, enteropathy, X-linked syndrome (APECED). J Med Genet. 38, 874–878.

Krutchkoff, D. L., Izzetoglu, M., Giron, W. D., Johnson, T., Reddick, D., Walczak, P., Sager, W. P., Chen, H. H., Pettengel, J., Udabage, I., Young, R. G., Marcilino, M., Pittenger, F. M., Solomon, M., Bostrom, R. C., Toome, B. R., Waldb, L., and Rabe, J. W. (2007). Dynamic imaging of allogeneic mesenchymal stem cell trafficking to myocardial infarction. Circulation 115, 1651–1661.

Le Blan, K., Force, F., Bell, L., Locatelli, F., Rosolli, E., Levis, I., Laino, E., Sindberg, B., Berard, M. E., Rembong, M., Dixi, G., Egeler, R. M., Bacigalupo, A., Fabbri, W., Ringden, O., and Developmental Committee of the European Group for Blood and Marrow Transplantation (2008). Mesenchymal stem cells for treatment of erosional, severe, acute graft-versus-host disease: a phase II study. Leuk Lymph 57, 1579–1586.

Le Blan, K., Rammens, L., Sandberg, B., Goethem, C., Has- man, M., Ummel, M., and Ring- den, O. (2004). Treatment of severe acute graft-versus-host disease with third party haplidentical mesenchymal stem cells. Transplantation 78, 1443–1447.

Liu, W., Putnam, A. L., Xu, Y., Jort, G. L., Lee, M. K., Zhu, S., Giffick, P. A., Karpuzov, P. G., Tang, G., Xu, J., Pettinger, C., Soper, D. M., Ziegler, S. F. and Blau, H. M. (2010). CD127 expression increases immunosuppressive function of Fas+ and suppressive function of human CD127+ and TGF-beta+ T cells. J Immunol 184, 1703–1711.

Ma, A., Xu, S., Song, L., Hu, Y., Yan, B., Mastrucci, E., Dupuis, M., Dalesio, P. and Chen, H. (2011). Adoptive transfer of CD127+CD28- regulatory cell combinations with low density and anti-therapeutic globulin delayed acute rejection of renal allografts in Cynomolgus monkeys. Int J Immunopharmacol. 11, 618–629.

Moura, R., Podestia, M., Moretti, A., Cometa, A., Comel, P., Montagna, D., Dusi, L., Bratci, A., Piaggio, P., Zenzi, S., Frezioni, S. and Locatelli, F. (2003). Interaction of human mesenchymal stem cells with cells involved in autoimmune-like systemic immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90, 516–525.

McHugh, R. S., Whitmore, J. M., Picciotto, C. A., Young, D. A., Sher- vash, E. M., Collins, M., and Byrns, M. C. (2002). CD46 (C3d/2b)-mediated immunoregulatory T cells gene expression analysis reveals a functional role for the ghrelinergic-induced TNP receptor immunity 16, 311–322.

McMurchy, A. N., Bushell, A., Leger, S. M., and Reed, R. J. (2011). Moving to tolerance: clinical application of T regulatory cells. Curr Opin Immunol 23, 308–313.

Meul, K., Zikber, A., Lypa, M., Gebel, U., Danenberg, W., and Dilsen, D. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103, 4619–4621.

Moneiro, M., Almeida, C. F., Carvalho, M., Ribeir, J. C., Durao, J., Agui- Dao, A., Wolkenberg, L., Silva-Santos, B., and Goura, L. (2010). Identification of regulatory Foxp3+ intratumal NKT cells induced by TGF-beta. J Immunol 185, 2157–2165.

Nadil, S. N., Waskowka, J., Wu, D. C., Warmack, G., Zhang, W., Loo, S., Schipper, A., Taggert, D. P., and Wood, E. J. (2010). In vivo protection of transplant arteriosclerosis by Naive Treg in expanded human regulatory T cells. Stem Cells 28, 1242–1252.

Naef, A., Mathias, N., Chapell, A., Fried, K., Srinivas, S., Marzetti, C., Boursia, A., Beschet, S., Gour, N. C., Thiery, D., and Foulard, L. (2010). Immunomodulatory effects of mesenchymal stem cell involvement of HLA-G. Transplantation 94, 231–237.

Nara, A. J., Krausz, D. R., Lee, V. J., Gotta, E., Todeschini, M., Cavinato, R., Gori, E., Todeschini, C., and Fouillard, L. (2008). Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow. Stem Cells Dev 26, 151–162.

Raul, S., McElrath, V. and Pavone, F. (2000). Cytoytic T lymphocyte-associated antigen 4 plays an essential role in the function of CD4+CD25+ regulatory cells that control intestinal inflammation. J Exp Med 192, 295–302.

Rathi, R., Garbi, N., Gano, R., Ham- moting, G. I., Arnold, B., and Osler, T. (2006). CD4+ regulatory T cells generated by maternal recognition of cervical self-antigens. Proc Natl Acad Sci U S A 103, 15142–15147.

Reibke, R., Garbi, N., Ganss, R., Ham- moting, G. J., Arnold, B., and Oelert, H. J., and Dahlke, M. H. (2008). TGF beta-induced TNF receptor. Curr Opin Immunol 19, 315–321.

Riviere, A., Moerman, F., and Fazekas de St Groth, B. (2004). Expression of interleukin (IL)-2 and IL-7 receptors distinguishes between human regulatory and activated T cells. J Exp Med 205, 1691–1699.

Riviere, A., Naji, A., Zikli, I., Farier, B., Guelff, E., Obert, L., Borg, C., Saas, P., Tibeuleog, P., Rosan, Freres, N., Carnoloda, E. D., and Danchin, E. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lympho- cyte-cytotoxic and killer function and to induce CD42 /CD8+ T cells regulatory T cells. Stem Cells Dev 20, 212–226.

Suga, S., Gu, I., Itou, H., Shi, X., Hu, Y., Feng, L., and Ding, Y. T. (2010). Mag- netically labeled mesenchymal stem cells after autotransplantation into acutely injured liver. World J Gastroenterol 16, 8744–8749.

Sotomayor, E., Lamy, S., Takahashi, T., Ishida, Y., and Sakaguchi, S. (2002). Stimulation of CD28(-)CD4+ T regulatory cell through GITR breaks immunological self-tolerance. Nature Immunol 3, 990–997.

Shin, H. J., Baker, J., Loveness-Gower, D. B., Smith, A. T., Sego, E. J., and Nagar, R. S. (2011). Rapamycin and IL-2 reduce lethal acute graft- versus-host disease associated with increased expression of donor type CD42 /CD8+ T cells regulatory T cells. Blood 118, 2452–2455.

Stoppsdorff, P. A., Perreira, S. A., Gottar- dia, A. D., Bencok, E. C., and Papamichail, M. (2006). Interactions expressed by human mesenchymal stem cells and natural killer cells. Stem Cells 24, 74–85.
Engela et al. Interactions between MSC and Treg

Spaggiari, G. M., Abdulrazik, H., Becchetti, F., and Moretta, L. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113, 4576–4583.

Takashi, T., Tagami, T., Yomazaki, S., Uede, T., Shimizu, J., Sakaguchi, S., Mak, T. W., and Sakaguchi, S. (2010). Immunological self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303–310.

Tang, Q., and Bluestone, J. A. (2008). The Foxp3(+) regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9, 239–244.

Takata, R., Ozaki, K., Kikuchi, Y., Hatanaka, K., Oh, I., Meguro, A., Matsu, H., Sato, K., and Ozawa, K. (2011). Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy 13, 686–694.

Thornton, A. M., Korty, P. E., Tran, D. Q., Wolfert, E. A., Murray, P. E., Belkaud, Y., and Shevach, E. M. (2010). Expression of Helios, an IkappaBalpha transcription factor family member, differentiates thymic and peripheral regulatory T cells. J. Immunol. 184, 3433–3441.

Trzonkowski, P., Bieniaszewska, M., Basinski, J., Dobrowski, A., Krysztofik, A., Marek, W., Myśliwa, J., and Hollmann, A. (2009). First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4(+)CD25(+)CD127(-) regulatory T cells. Clin. Immunol. 133, 22–26.

Wieczorek, G., Asemissen, A., Model, F., Turchova, I., Floess, S., Liebenberg, V., Baron, U., Stauch, D., Kotsch, K., Pratschke, J., Hamann, A., Ledinkemper, C., Steur, H., Volk, H. D., Hoffmuller, U., Grätzkou, A., Mouts, A., Hu-Lies, J., Schoenenburg, C., and Olsch, S. (2009). Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissues. Cancer Res. 69, 590–608.

Ziegler, S. F. (2006). FOXP3: of mice and men. Annu. Rev. Immunol. 24, 209–226.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 03 April 2012; paper pending publication: 25 April 2012; accepted: 03 May 2012; published online: 18 May 2012.

Zuk, P. A., Zhu, M., Ashjian, P., De Ugarte, D. A., Huang, J. I., Mizuno, H., Alfonso, Z. C., Benhaim, P., and Hedrick, M. H. (2002). Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 13, 4279–4295.

Copyright © 2012 Engela, Baan, Dor, Weimar and Hoogduijn. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.